|
New Phase 3 Study Results Show Anti-TNF SIMPONI® Induced Clinical Response in Adults With Moderately to Severely ...
SAN DIEGO, May 21, 2012 /PRNewswire/ -- New study findings presented today show that subcutaneous induction regimens of the anti-tumor necrosis factor (TNF)-alpha therapy SIMPONI® (golimumab) induced clinical ...
finance.yahoo.com
Sufferer wants people to talk more about illness
Living with inflammatory bowel disease makes "leading a normal life virtually impossible", a 27-year-old sufferer says.
www.stuff.co.nz
Bowel cancer: 14 deaths in Coleraine
ALMOST 40 people are diagnosed and 14 die from bowel cancer in the Coleraine Borough Council area every year.
www.colerainetimes.co.uk
Santarus Announces Presentation of UCERIS Phase III Extended Use Data at Digestive Disease Week Meeting
Santarus, Inc. today announced that safety and efficacy data from a Phase III, double-blind, multicenter, placebo-controlled 12 month extended use study with the inv
finance.yahoo.com
Dr. Paul Donohue: Long-term laxative use is safe
Dear Dr. Donohue: I know nothing about MiraLax, but my doctor suggested using it daily. It seems to be working fine. Back in 2009, I had a colonoscopy, and another doctor recommended Citrucel. Is it similar to MiraLax? MiraLax is called a laxative, and I thought that one should not take a laxative daily. It's an osmotic laxative. What's that? I am in my 80s and have always been troubled with ...
www.detroitnews.com
Press Release
Santarus Inc. Posted on:18 May 12 Santarus, Inc . (NASDAQ: SNTS) today announced that safety and efficacy data from a Phase III, double-blind, multicenter, placebo-controlled 12 month extended use study with the investigational drug UCERIS™ (budesonide) 6 mg tablets (previously referred to as budesonide MMX®) will be featured in four poster presentations at the Digestive Disease Week (DDW® ...
www.pharmiweb.com
Anger: How to Recognize and Deal with a Common Emotion
Q&A on recognizing and dealing with anger.
www.newswise.com
|
